AXIM Biotech, In Proof-of-Concept Study for RLS Treatment, Reports Second Quarter 2017 Results
AXIM Biotechnologies Inc announced results for the quarter ended June 30, 2017, and provided an overview of recent operational highlights. “The development of cannabinoid-based therapeutics continues to gather momentum in the US...